Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients

Virology Journal

Gui Qiang Wang²  Shi Hong Li²  Yuan Yuan Ren²  Peng Ding¹  Feng Qin Hou²  Yong Zhe Liu² 

[1] College of Public Health, Hebei United University, Hebei province, 063000, People's Republic of China;Department of Infectious Diseases and Research Center for Liver Diseases, Peking University First Hospital, Beijing, 100034, People’s Republic of China

关键词: Intracytoplasmic cytokine staining (ICCS);    Memory T cell;    Pegylated interferon-α therapy;    Chronic hepatitis B;   

Others  :  1153189
DOI  :  10.1186/1743-422X-9-274

 received in 2012-02-24, accepted in 2012-11-13,  发布年份 2012

【 摘 要 】

Background

Interferons (IFNs) are a group of cytokines commonly used in the clinical treatment of chronic hepatitis B (CHB) patients. Their therapeutic effects are highly correlated with recovery of host antiviral immunity. Clearance of hepatitis B virus (HBV) is mediated partially by activated functional memory T cells. The aims of the present study were to investigate memory T cell status in patients with different outcomes following pegylated interferon-α (IFN-α) therapy and to identify new biomarkers for predicting antiviral immune responses.

Methods

Peripheral blood cells were isolated from 23 CHB patients who were treated with pegylated IFN-α at week 0 (baseline) and week 24. Co-expression of programmed death-1 (PD-1) and CD244 in CD45RO positive T cells, as well as a subset of CD127 and CXCR4 positive memory T cells were assessed. In addition, perforin, granzyme B, and interferon-γ (IFN-γ) expressions were also analyzed by flow cytometric analysis after intracytoplasmic cytokine staining (ICCS). Peripheral blood mononuclear cells (PBMC) isolated at week 24 were re-challenged with exogenous HBV core antigen, and the percentage of IFN-γ expression, serum HBV DNA loads, and ALT (alanine aminotransferase) levels were evaluated.

Results

At week 24, PD-1 and CD244 expression in CD8 memory T cells were down-regulated (P < 0.05, P < 0.05, respectively), along with decreased HBV DNA loads (P < 0.05), while the expressions of partial effector molecules in CD8 and CD4 memory T cells was up-regulated (P < 0.05,P < 0.05, respectively), especially in the responders. CD127 and CXCR4 were highly expressed in CD8 memory T cells after pegylated IFN-α treatment (P < 0.05), which was inversely correlated with HBV DNA loads (r = −0.47, P = 0.001). The responders had a higher IFN-γ expression in memory T cells than the non-responders did after HBV antigen re-stimulation in vitro.

Conclusion

Pegylated IFN-α treatment enhanced recovery of memory T cells in CHB patients by down-regulating inhibitory receptors and up-regulating effector molecules. The expressions of CXCR4 and CD127 in CD8 memoryT cell may be used as biomarkers for predicting the outcome of treatment.

【 授权许可】

   
2012 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Dienstag JL: Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
• [2]Lok AS, McManhon BJ: Chronic hepatitis B. Hepatology 2001, 34:1225-1241.
• [3]Rehermann B, Nascimbeni M: Immunology of Hepatitis B virus and Hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229.
• [4]Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov NV, Ferrari C, Bertoletti A: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000, 191:1269-1280.
• [5]Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R: Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
• [6]Sobao Y, Tomiyama H, Sugi K, Tokunaga M, Ueno T, Saito S, Fujiyama S, Morimoto M, Tanaka K, Takiguchi M: The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002, 36:105-115.
• [7]Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, Cavalli A, Petit MA, Fiaccadori F: Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990, 145:3442-3449.
• [8]Malmgaard L: Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004, 24:439-454.
• [9]Guidotti LG, Morris A, Mendez H, Koch R, Silverman RH, Williams BR, Chisari FV: Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002, 76:2617-2621.
• [10]Wieland SF, Guidotti LG, Chisari FV: Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000, 74:4165-4173.
• [11]Wherry EJ, Ahmed R: Memory CD8 T-cell differentiation during viral infection. J Virol 2004, 78:5535-5545.
• [12]Campbell DJ, Kim CH, Butcher EC: Chemokines in the systemic organization of immunity. Immunol Rev 2003, 95:58-71.
• [13]Marinos G, Torre F, Chokshi S, Hussain M, Clarke BE, Rowlands DJ, Eddleston AL, Naoumov NV, Williams R: Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. Hepatology 1995, 22:1040-1049.
• [14]Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV: Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:35-36.
• [15]Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007, 81:4215-4225.
• [16]Bertoletti A, Ferrari C: Kinetics of the immune response during HBV and HCV infection. Hepatology 2003, 38:4-13.
• [17]Urbani S, Boni C, Missale G, Elia G, Cavallo C, Massari M, Raimondo G, Ferrari C: Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol 2002, 76:12423-12434.
• [18]Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
• [19]Kaech SM, Hemby S, Kersh E, Ahmed R: Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111:837-851.
• [20]Harty JT, Badovinac VP: Influence of effector molecules on the CD8+ T cell response to infection. Curr Opin Immunol 2002, 14:360-365.
• [21]Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B, Wang GQ: Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res 2010, 60:47-53.
• [22]Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, Pircher H, Thimme R: Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010, 6:e1000947.
• [23]Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G, Ferrari C: Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010, 138:682-693.
• [24]Raziorrouh B, Schraut W, Gerlach T, Nowack D, Grüner NH, Ulsenheimer A, Zachoval R, Wächtler M, Spannagl M, Haas J, Diepolder HM, Jung MC: The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010, 52:1934-1947.
• [25]Chen J, Wang Y, Wu XJ, Li J, Hou FQ, Wang GQ: Pegylated interferonα-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B. World J Gastroenterol 2010, 16:6145-6150.
• [26]Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H, Franitza S, Weiss I, Avniel S, Boaz P, Hanna J, Zamir G, Eid A, Mandelboim O, Spengler U, Galun E, Peled A: Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004, 34:1164-1174.
• [27]Kumar A, Humphreys TD, Kremer KN, Bramati PS, Bradfield L, Edgar CE, Hedin KE: CXCR4 physically Associates with the T Cell Receptor to Signal in T Cells. Immunity 2006, 25:213-224.
• [28]Furusato B, Mohamed A, Uhlén M, Rhim JS: CXCR4 and cancer. Pathol Int 2010, 60:497-505.
• [29]Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Marullo S, Viola A: CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci 2008, 105:10101-10106.
• [30]Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003, 4:225-234.
• [31]Wherry EJ, Day CL, Draenert R, Miller JD, Kiepiela P, Woodberry T, Brander C, Addo M, Klenerman P, Ahmed R, Walker BD: HIV-specific CD8 T cells express low levels of IL-7R alpha: implications for HIV-specific T cell memory. Virology 2006, 353:366-373.
• [32]Lv G, Ying L, Ma WJ, Jin X, Zheng L, Li L, Yang Y: Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment. Virol J 2010, 7:207. BioMed Central Full Text
• [33]Colle JH, Moreau JL, Fontanet A, Lambotte O, Joussemet M, Delfraissy JF, Thèze J: CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients–reversal by highly active anti-retroviral therapy (HAART). Clin Exp Immunol 2006, 143:398-403.
• [34]Lang KS, Recher M, Navarini AA, Harris NL, Löhning M, Junt T, Probst HC, Hengartner H, Zinkernagel RM: Inverse correlation between IL-7 receptor expression and CD8 T cell exhaustion during persistent antigen stimulation. Eur J Immunol 2005, 35:738-745.
• [35]Zhang SY, Zhang Z, Fu JL, Kang FB, Xu XS, Nie WM, Zhou CB, Zhao M, Wang FS: Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection. Eur J Immunol 2009, 39:1425-1434.
• [36]Bertoletti A, Maini MK, Ferrari C: The host–pathogen interaction during HBV infection: immunological controversies. Antivir Ther 2010, 15(suppl 3):15-24.
• [37]Dunn C: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009, 137:1289-1300.
• [38]Makedonas G, Hutnick N, Haney D, Amick AC, Gardner J, Cosma G, Hersperger AR, Dolfi D, Wherry EJ, Ferrari G, Betts MR: Perforin and IL-2 Upregulation define qualitative differences among highly functional virus-specific human CD8+ T Cells. PLoS Pathog 2010, 6:e1000798.
• [39]Chinese Society of Hepatology and Chinese Society of Infectious Diseases: Guideline on prevention and treatment of chronic hepatitis B in China. Chin Med J (Engl) 2007, 24:2159-2173.